EA201591683A1 - Способы лечения, снижения частоты и/или профилактики ишемических событий - Google Patents
Способы лечения, снижения частоты и/или профилактики ишемических событийInfo
- Publication number
- EA201591683A1 EA201591683A1 EA201591683A EA201591683A EA201591683A1 EA 201591683 A1 EA201591683 A1 EA 201591683A1 EA 201591683 A EA201591683 A EA 201591683A EA 201591683 A EA201591683 A EA 201591683A EA 201591683 A1 EA201591683 A1 EA 201591683A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- frequency
- methods
- ischemic event
- patient
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Способы лечения, снижения частоты и/или профилактики ишемического события у пациента, подвергаемого чрескожной коронарной ангиопластике (PCI), включающий введение пациенту фармацевтической композиции, содержащей кангрелор. Способ может дополнительно включать введение пациенту дополнительного терапевтического средства, где дополнительное терапевтическое средство содержит ингибитор P2Y. Фармацевтические композиции, пригодные для лечения, снижения частоты и/или профилактики ишемического события у пациента, подвергаемого PCI. Фармацевтические композиции содержат кангрелор. Способы получения фармацевтической композиции для лечения, снижения частоты и/или профилактики ишемического события у пациента, подвергаемого PCI, включающие смешивание кангрелора с одним или несколькими фармацевтически приемлемыми эксципиентами. Ишемическое событие может включать тромбоз стента, инфаркт миокарда, обусловленную ишемией реваскуляризацию и смертельный исход.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/792,056 US9427448B2 (en) | 2009-11-11 | 2013-03-09 | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
US201361815735P | 2013-04-25 | 2013-04-25 | |
PCT/US2013/043136 WO2014143107A1 (en) | 2013-03-09 | 2013-05-29 | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201591683A1 true EA201591683A1 (ru) | 2016-08-31 |
EA034550B1 EA034550B1 (ru) | 2020-02-19 |
Family
ID=51537409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591683A EA034550B1 (ru) | 2013-03-09 | 2013-05-29 | Способы лечения, снижения частоты и/или профилактики ишемических событий |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP2964233B1 (ru) |
JP (3) | JP6247708B2 (ru) |
CN (2) | CN106102750A (ru) |
AU (1) | AU2013381855B2 (ru) |
BR (1) | BR112015022070B1 (ru) |
CA (1) | CA2904523C (ru) |
EA (1) | EA034550B1 (ru) |
ES (1) | ES2904256T3 (ru) |
PL (1) | PL2964233T3 (ru) |
WO (1) | WO2014143107A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019015448A (es) * | 2017-06-23 | 2020-02-19 | Chiesi Farm Spa | Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar. |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69406649T2 (de) | 1993-02-10 | 1998-03-05 | Astra Pharma Prod | N-alkyl-2-substituierte atp-analoge |
ID21635A (id) | 1996-12-20 | 1999-07-08 | Astra Pharma Prod | Komposisi farmasi untuk pengeringan beku |
SE9702680D0 (sv) | 1997-07-11 | 1997-07-11 | Astra Pharma Prod | New formulation |
SE9904377D0 (sv) | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
WO2009140092A1 (en) * | 2008-05-13 | 2009-11-19 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
US20100297675A1 (en) * | 2008-11-24 | 2010-11-25 | Huayun Deng | Substrate and method for culturing breast cells |
CA2778880C (en) * | 2009-11-11 | 2018-02-13 | The Medicines Company | Methods of treating or preventing stent thrombosis |
-
2013
- 2013-05-29 AU AU2013381855A patent/AU2013381855B2/en active Active
- 2013-05-29 ES ES13878203T patent/ES2904256T3/es active Active
- 2013-05-29 CA CA2904523A patent/CA2904523C/en active Active
- 2013-05-29 WO PCT/US2013/043136 patent/WO2014143107A1/en active Application Filing
- 2013-05-29 CN CN201380076382.XA patent/CN106102750A/zh active Pending
- 2013-05-29 PL PL13878203T patent/PL2964233T3/pl unknown
- 2013-05-29 EA EA201591683A patent/EA034550B1/ru unknown
- 2013-05-29 EP EP13878203.2A patent/EP2964233B1/en active Active
- 2013-05-29 JP JP2015561314A patent/JP6247708B2/ja active Active
- 2013-05-29 BR BR112015022070-3A patent/BR112015022070B1/pt active IP Right Grant
- 2013-05-29 EP EP21205348.2A patent/EP3978002A1/en active Pending
- 2013-05-29 CN CN202210682855.1A patent/CN115120606A/zh active Pending
-
2017
- 2017-10-11 JP JP2017197488A patent/JP2018002739A/ja not_active Withdrawn
-
2019
- 2019-07-26 JP JP2019137721A patent/JP6840197B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2018002739A (ja) | 2018-01-11 |
AU2013381855A1 (en) | 2015-10-22 |
EP3978002A1 (en) | 2022-04-06 |
JP2019178177A (ja) | 2019-10-17 |
JP2016510738A (ja) | 2016-04-11 |
PL2964233T3 (pl) | 2022-04-25 |
WO2014143107A1 (en) | 2014-09-18 |
EP2964233A1 (en) | 2016-01-13 |
CN106102750A (zh) | 2016-11-09 |
BR112015022070A2 (pt) | 2017-07-18 |
CA2904523C (en) | 2024-01-09 |
EP2964233B1 (en) | 2021-12-15 |
JP6247708B2 (ja) | 2017-12-13 |
EA034550B1 (ru) | 2020-02-19 |
CA2904523A1 (en) | 2014-09-18 |
JP6840197B2 (ja) | 2021-03-10 |
AU2013381855B2 (en) | 2018-08-02 |
CN115120606A (zh) | 2022-09-30 |
ES2904256T3 (es) | 2022-04-04 |
EP2964233A4 (en) | 2016-10-19 |
BR112015022070B1 (pt) | 2022-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
MX2021008610A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
MX2019008696A (es) | Compuestos de piridina como inhibidores de shp2 alostericos. | |
MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
EA201892510A2 (ru) | Комбинированная терапия для лечения рака | |
BR112016011949A2 (pt) | Composto, composição farmacêutica, e, uso dos mesmos | |
EA201690980A1 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
MX2015012760A (es) | Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
EA201391286A1 (ru) | Лечение солидных опухолей | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
BR112016000335A8 (pt) | método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica | |
RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
WO2015095838A3 (en) | Cancer treatments using combinations of mek type i and erk inhibitors | |
RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
WO2014186623A3 (en) | Methods and compositions for the treatment of a chagas disease | |
BR112022019914A2 (pt) | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
MX2019002121A (es) | Tratamiento conjunto para tratar el cancer de pancreas. |